Clinical Trials Logo

Clinical Trial Summary

The absence of a boosting response after a 14 day interval with the two-dose regimen of the modified killed oral cholera vaccine raises the possibility that a longer dosing interval may be required to observe a boost in the immune response. This study will compare the immune responses following 14-day and 28-day dosing intervals.


Clinical Trial Description

Cholera is a re-emerging infectious disease that causes significant morbidity and mortality in populations lacking access to safe drinking water and sanitation. Provision of safe drinking water and food, establishment of adequate sanitation, and implementation of personal and community hygiene constitute the main public health interventions against cholera. These measures cannot be implemented fully in the near future in most cholera-endemic areas. Improvements to water and sanitation require substantial long-term investments, commitment from the local government and often take years to implement. In the meantime, a safe, effective, and affordable vaccine would be a useful tool for cholera prevention and control.

Considerable progress has been made during the last decade in the development of new generation oral cholera vaccines against cholera. A monovalent (anti-O1) WC-rBS oral killed cholera vaccine with a B-subunit was developed by Professor Jan Holmgren in Sweden and is sold primarily as a traveler's vaccine; and is only WHO pre-qualified vaccine till date. A version of this vaccine that lacks the B subunit and is considerably less expensive to produce ("whole-cell only") and which is now bivalent (O1 and O139), has been produced and used exclusively in Vietnam, making it the first oral cholera vaccine used primarily for endemic populations.

To internationalize the use of this improved vaccine, its production technology was modified to comply with the WHO Manufacturing practices (cGMP) standards before its manufacturing technology was transferred to an Indian manufacturing company Shantha Biotechnics Limited by the International Vaccine Institute. The modified killed bivalent oral cholera vaccine has been recently licensed by the Drugs Controller General of India (DCGI) to the Shantha Biotechnics Limited and being marketed as Shancol ® after phase II and Phase III clinical trials. It is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above. It was found safe, effective and provided 67% protection after two years in a placebo-controlled, randomized trial in Kolkata, India.

Despite the recent licensure, there are remaining questions that need to be answered that would be vital in deploying the vaccine including optimization of dosing regimen. A previous study performed in Kolkata revealed that two doses of the vaccine when given 14 days apart did not result in higher immune response after the first dose, contrary to earlier findings with the Swedish vaccine. This new finding may be due to the higher lipopolysaccharide (LPS) content of the modified vaccine which may have elicited sufficient immune response that it effectively blocks subsequent antigen presentation with the second dose of the vaccine.

In order to assess if immune responses will be boosted if we prolong the interval between dosing of the modified killed oral cholera vaccine, a Phase II double-blind, controlled, randomized trial to evaluate two different dosing interval schedules for the two-dose regimen will be conducted. This study will compare the immune responses following 14-day and 28-day dosing intervals. In addition to the 356 subjects for the main study, 30 subjects will be enrolled to explore the possibility of any other immunological marker for vibrio cholera infection. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01233362
Study type Interventional
Source International Vaccine Institute
Contact
Status Completed
Phase Phase 2
Start date December 2010
Completion date February 2013

See also
  Status Clinical Trial Phase
Completed NCT01895855 - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Phase 3
Completed NCT01339845 - Introduction of Cholera Vaccine in Bangladesh N/A
Recruiting NCT05829772 - Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
Completed NCT04760236 - Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shancholâ„¢ Phase 3
Recruiting NCT04326478 - Single Dose Azithromycin to Prevent Cholera in Children Phase 2
Recruiting NCT06104345 - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines Phase 4
Completed NCT02928341 - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo N/A
Completed NCT02864433 - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Recruiting NCT06003816 - Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI) N/A
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT04150250 - Cholera Anti-Secretory Treatment Trial Phase 2
Terminated NCT00624975 - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Phase 2
Completed NCT00226616 - Zinc Supplementation in Cholera Patients Phase 3
Completed NCT03373669 - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Phase 4
Completed NCT02094586 - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults Phase 3
Completed NCT02100631 - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase 3
Completed NCT01823939 - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Phase 1
Completed NCT01365442 - Pilot Introduction of Oral Cholera Vaccine in Orissa, India N/A
Completed NCT00128011 - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Phase 2
Completed NCT00672308 - Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Phase 2